Abstract Details

Title Defining Utility Values for Chorea Health States in Patients With Huntington’s Disease

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 044

Objective

To estimate the impact on quality of life (QOL) of different severity levels of chorea associated with Huntington’s disease (HD) using utility values from the general population.

Background Chorea is characterized by sudden, involuntary movements that may interfere with QOL. Utility values measure preferences for different health states and reflect societal perceived disease severity. They are used by decision-makers to more accurately estimate treatment benefit. To date, no studies have reported utility values specifically for HD chorea.

Design/Methods Participants representative of the general population were enrolled using computer-assisted telephone interviews to elicit HD chorea utility values. Participants were asked to read vignettes describing 4 health states for varying levels of chorea severity, with the same underlying HD severity. Time tradeoff (TTO) methods were used to estimate utility values, which range from –1 (worse than death) to +1 (perfect health) and represent the number of years in an imperfect health state an individual is willing to give up to live in full health. TTO utilities were augmented with Visual Analogue Scale (VAS) participant responses. The primary outcome was HD chorea utility estimated by TTO.

Results TTO-derived utility values (n=155) increased as chorea severity decreased (mean±SD: severe, 0.07±0.52; moderate/severe, 0.26±0.50; moderate/mild, 0.48±0.47; mild, 0.64±0.41). Differences between each health state and its adjacent less severe health state were statistically significant (all P<0.0001). Respondents were willing to give up 3.6, 5.2, 7.4 and 9.3 years during a 10-year lifespan to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively. VAS and TTO results were consistent.

Conclusions

Significant decreases in utility values were seen as severity of HD chorea increased, suggesting that participants recognize the negative impact of HD chorea on daily functioning and QOL. These values can be leveraged for cost-effectiveness modeling to better understand the value of treatments for chorea.

Authors/Disclosures
PRESENTER	No disclosure on file
Daniel O. Claassen, MD, F�鶹��ýӳ�� (Vanderbilt University Medical Center)	Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.
	No disclosure on file
	No disclosure on file
Sam Leo, PharmD (Teva)	Dr. Leo has received personal compensation for serving as an employee of Teva Pharmaceutical Industries.
	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��